Evidence map›Paper›PMID 29546645›Full record

ArticleDigestive diseases and sciences2018

Subtypes of the Type II Pit Pattern Reflect Distinct Molecular Subclasses in the Serrated Neoplastic Pathway.

Hironori Aoki, Eiichiro Yamamoto, Hiro-O Yamano, Tamotsu Sugai, Tomoaki Kimura, Yoshihito Tanaka, Hiro-O Matsushita, Kenjiro Yoshikawa, Ryo Takagi, Eiji Harada and 12 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Molecular alterations in gastric cancer and the surrounding intestinal metaplastic mucosa: an analysis of isolated glands.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2021
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 5 institutions in 1 country.

Hironori AokiDepartment of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan.
Eiichiro YamamotoDepartment of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan.
Hiro-O YamanoDepartment of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Tamotsu SugaiDepartment of Molecular Diagnostic Pathology, Iwate Medical University, Morioka, Japan.
Tomoaki KimuraDepartment of Digestive Disease Center, Akita Red Cross Hospital, Akita, Japan.
Yoshihito TanakaDepartment of Digestive Disease Center, Akita Red Cross Hospital, Akita, Japan.
Hiro-O MatsushitaDepartment of Digestive Disease Center, Akita Red Cross Hospital, Akita, Japan.
Kenjiro YoshikawaDepartment of Digestive Disease Center, Akita Red Cross Hospital, Akita, Japan.
Ryo TakagiDepartment of Digestive Disease Center, Akita Red Cross Hospital, Akita, Japan.
Eiji HaradaDepartment of Digestive Disease Center, Akita Red Cross Hospital, Akita, Japan.
Michiko NakaokaDepartment of Digestive Disease Center, Akita Red Cross Hospital, Akita, Japan.
Yuko YoshidaDepartment of Digestive Disease Center, Akita Red Cross Hospital, Akita, Japan.
Taku HaradaDepartment of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan.
Gota SudoDepartment of Gastroenterology, Teine-Keijinkai Hospital, Sapporo, Japan.
Makoto EizukaDepartment of Molecular Diagnostic Pathology, Iwate Medical University, Morioka, Japan.
Akira YorozuDepartment of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan.
Hiroshi KitajimaDepartment of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan.
Takeshi NiinumaDepartment of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan.
Masahiro KaiDepartment of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan.
Masanori NojimaCenter for Translational Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Hiromu SuzukiDepartment of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan. hsuzuki@sapmed.ac.jp.ORCID http://orcid.org/0000-0001-9635-3238
Hiroshi NakaseDepartment of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Sapporo Medical University · JPAkita Red Cross Hospital · JPIwate Medical University · JPTeine Keijinkai Hospital · JPThe University of Tokyo · JP

Funding

JSPS KAKENHI 15H04299JSPS KAKENHI 15K08973JSPS KAKENHI 15K19339
6 · The paper itself

Abstract

backgroundColorectal serrated lesions (SLs) are important premalignant lesions whose clinical and biological features are not fully understood.

aimsWe aimed to establish accurate colonoscopic diagnosis and treatment of SLs through evaluation of associations among the morphological, pathological, and molecular characteristics of SLs.

methodsA total of 388 premalignant and 18 malignant colorectal lesions were studied. Using magnifying colonoscopy, microsurface structures were assessed based on Kudo's pit pattern classification system, and the Type II pit pattern was subcategorized into classical Type II, Type II-Open (Type II-O) and Type II-Long (Type II-L). BRAF/KRAS mutations and DNA methylation of CpG island methylator phenotype (CIMP) markers (MINT1, - 2, - 12, - 31, p16, and MLH1) were analyzed through pyrosequencing.

resultsType II-O was tightly associated with sessile serrated adenoma/polyps (SSA/Ps) with BRAF mutation and CIMP-high. Most lesions with simple Type II or Type II-L were hyperplastic polyps, while mixtures of Type II or Type II-L plus more advanced pit patterns (III/IV) were characteristic of traditional serrated adenomas (TSAs). Type II-positive TSAs frequently exhibited BRAF mutation and CIMP-low, while Type II-L-positive TSAs were tightly associated with KRAS mutation and CIMP-low. Analysis of lesions containing both premalignant and cancerous components suggested Type II-L-positive TSAs may develop into KRAS-mutated/CIMP-low/microsatellite stable cancers, while Type II-O-positive SSA/Ps develop into BRAF-mutated/CIMP-high/microsatellite unstable cancers.

conclusionsThese results suggest that Type II subtypes reflect distinct molecular subclasses in the serrated neoplasia pathway and that they could be useful hallmarks for identifying SLs at high risk of developing into CRC.

Indexed as

Adenomatous PolypsAgedAged, 80 and overBiomarkers, TumorCell Transformation, NeoplasticColonic PolypsColonoscopyColorectal NeoplasmsCpG IslandsDNA MethylationDNA Mutational AnalysisFemaleGenetic Predisposition to DiseaseHumansJapanMaleBiomarkers, TumorColonoscopyColorectal neoplasmsDNA methylationMutationPit patternSerrated lesion

Identifiers

PMID29546645
OpenAlexW2793988929

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.